Safiri, S. et al. Global, regional and national burden of osteoarthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann. Rheum. Dis. 79, 819–828 (2020).
Bijlsma, J. W., Berenbaum, F. & Lafeber, F. P. Osteoarthritis: an update with relevance for clinical practice. Lancet (Lond., Engl.) 377, 2115–2126 (2011).
Turkiewicz, A. et al. Current and future impact of osteoarthritis on health care: a population-based study with projections to year 2032. Osteoarthr. Cartil. 22, 1826–1832 (2014).
Wei, Y. & Bai, L. Recent advances in the understanding of molecular mechanisms of cartilage degeneration, synovitis and subchondral bone changes in osteoarthritis. Connect. Tissue Res. 57, 245–261 (2016).
van der Kraan, P. M. & van den Berg, W. B. Osteophytes: relevance and biology. Osteoarthr. Cartil. 15, 237–244 (2007).
Robinson, W. H. et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 12, 580–592 (2016).
Hu, Y., Chen, X., Wang, S., Jing, Y. & Su, J. Subchondral bone microenvironment in osteoarthritis and pain. Bone Res. 9, 20 (2021).
Zhen, G. & Cao, X. Targeting TGFbeta signaling in subchondral bone and articular cartilage homeostasis. Trends Pharm. Sci. 35, 227–236 (2014).
Pap, T. & Korb-Pap, A. Cartilage damage in osteoarthritis and rheumatoid arthritis-two unequal siblings. Nat. Rev. Rheumatol. 11, 606–615 (2015).
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J. P. & Fahmi, H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 7, 33–42 (2011).
Troeberg, L. & Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim. Biophys. Acta 1824, 133–145 (2012).
Gracitelli, G. C., Moraes, V. Y., Franciozi, C. E., Luzo, M. V. & Belloti, J. C. Surgical interventions (microfracture, drilling, mosaicplasty, and allograft transplantation) for treating isolated cartilage defects of the knee in adults. Cochrane Database Syst. Rev. 9, Cd010675 (2016).
Angele, P. et al. Chondral and osteochondral operative treatment in early osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 24, 1743–1752 (2016).
Glyn-Jones, S. et al. Osteoarthritis. Lancet (Lond., Engl.) 386, 376–387 (2015).
Kolasinski, S. L. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 72, 220–233 (2020).
Bannuru, R. R. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 27, 1578–1589 (2019).
Bruyère, O. et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin. Arthritis Rheum. 49, 337–350 (2019).
Filardo, G. et al. Non-surgical treatments for the management of early osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 24, 1775–1785 (2016).
Heinegard, D. & Saxne, T. The role of the cartilage matrix in osteoarthritis. Nat. Rev. Rheumatol. 7, 50–56 (2011).
Bondeson, J., Wainwright, S., Hughes, C. & Caterson, B. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin. Exp. Rheumatol. 26, 139–145 (2008).
Mehana, E. E., Khafaga, A. F. & El-Blehi, S. S. The role of matrix metalloproteinases in osteoarthritis pathogenesis: an updated review. Life Sci. 234, 116786 (2019).
Knauper, V., Lopez-Otin, C., Smith, B., Knight, G. & Murphy, G. Biochemical characterization of human collagenase-3. J. Biol. Chem. 271, 1544–1550 (1996).
Wan, Y. et al. Selective MMP-13 inhibitors: promising agents for the therapy of osteoarthritis. Curr. Med Chem. 27, 3753–3769 (2020).
Mort, J. S. & Billington, C. J. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res. 3, 337–341 (2001).
Mitchell, P. G. et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J. Clin. Investig. 97, 761–768 (1996).
Bányai, L., Tordai, H. & Patthy, L. The gelatin-binding site of human 72 kDa type IV collagenase (gelatinase A). Biochem. J. 298, 403–407 (1994).
Overall, C. M. & Sodek, J. Initial characterization of a neutral metalloproteinase, active on native 3/4-collagen fragments, synthesized by ROS 17/2.8 osteoblastic cells, periodontal fibroblasts, and identified in gingival crevicular fluid. J. Dent. Res. 66, 1271–1282 (1987).
Renkiewicz, R. et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 48, 1742–1749 (2003).
Krzeski, P. et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res. Ther. 9, R109 (2007).
Milner, J. M., Patel, A. & Rowan, A. D. Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum. 58, 3644–3656 (2008).
Chou, P. Y., Su, C. M., Huang, C. Y. & Tang, C. H. The characteristics of thrombin in osteoarthritic pathogenesis and treatment. Biomed. Res. Int. 2014, 407518 (2014).
Wilkinson, D. J. et al. Matriptase induction of metalloproteinase-dependent aggrecanolysis in vitro and in vivo: promotion of osteoarthritic cartilage damage by multiple mechanisms. Arthritis Rheumatol. 69, 1601–1611 (2017).
Akhatib, B. et al. Chondroadherin fragmentation mediated by the protease HTRA1 distinguishes human intervertebral disc degeneration from normal aging. J. Biol. Chem. 288, 19280–19287 (2013).
Goldstein, L. A. et al. Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim. Biophys. Acta 1361, 11–19 (1997).
Park, J. E. et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274, 36505–36512 (1999).
Balaziova, E. et al. Dipeptidyl peptidase-IV activity and/or structure homologs (DASH): contributing factors in the pathogenesis of rheumatic diseases? Adv. Exp. Med. Biol. 575, 169–174 (2006).
Hamson, E. J., Keane, F. M., Tholen, S., Schilling, O. & Gorrell, M. D. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteom. Clin. Appl. 8, 454–463 (2014).
Dunshee, D. R. et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J. Biol. Chem. 291, 5986–5996 (2016).
Lee, K. N. et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 107, 1397–1404 (2006).
Keane, F. M., Nadvi, N. A., Yao, T. W. & Gorrell, M. D. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J. 278, 1316–1332 (2011).
Zhang, H. E. et al. Identification of novel natural substrates of fibroblast activation protein-alpha by differential degradomics and proteomics. Mol. Cell Proteom. 18, 65–85 (2019).
Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA 91, 5657–5661 (1994).
Rettig, W. J. et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl Acad. Sci. USA 85, 3110–3114 (1988).
Kelly, T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist. Updat. 8, 51–58 (2005).
Garin-Chesa, P., Old, L. J. & Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA 87, 7235–7239 (1990).
Cortez, E., Roswall, P. & Pietras, K. Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin. Cancer Biol. 25, 3–9 (2014).
Kou, X. et al. The Fas/Fap-1/Cav-1 complex regulates IL-1RA secretion in mesenchymal stem cells to accelerate wound healing. Sci. Transl. Med. 10, eaai8524 (2018).
Wei, H. et al. Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target. Cell Rep. 33, 108252 (2020).
Bauer, S. et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res. Ther. 8, R171 (2006).
Waldele, S. et al. Deficiency of fibroblast activation protein alpha ameliorates cartilage destruction in inflammatory destructive arthritis. Arthritis Res. Ther. 17, 12 (2015).
Hiraoka, A. et al. Cloning, expression, and characterization of a cDNA encoding a novel human growth factor for primitive hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA 94, 7577–7582 (1997).
Hiraoka, A. et al. Stem cell growth factor: in situ hybridization analysis on the gene expression, molecular characterization and in vitro proliferative activity of a recombinant preparation on primitive hematopoietic progenitor cells. Hematol. J. 2, 307–315 (2001).
留言 (0)